Alzheimer Disease, Parkinson Disease
Conditions
Keywords
Parkinson Disease, Alzheimer Disease, [18F] CFPyPB, GlyT1
Brief summary
The underlying goal of this study is to assess \[18F\] CFPyPB PET imaging as a tool to evaluate the activity of the GlyT1 receptors in the brain of Parkinson's Disease (PD) and Alzheimer Disease (AD) research participants.
Detailed description
Approximately 6 subjects with Parkinson disease, 6 subjects with Alzheimer disease and 20 healthy control subjects will be recruited to participate in this study. All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. Subjects will be asked to undergo a bolus injection of \[18F\] CFPyPB followed by serial PET imaging scans and plasma sampling for measurement of \[18F\] CFPyPB in plasma (both protein bound and free) over a period of up to 4 hours. The imaging analyses will be performed by an image-processing specialist who will remain masked to the procedures employed with each imaging acquisition. The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, \[18F\] CFPyPB. Time to the peak uptake and amplitude of the peak uptake will be evaluated for all brain regions and the results for the PD and AD subjects will be compared with the HC subjects. At least 2 weeks following the initial imaging visit subjects (up to 2 PD subjects, up to 2 AD subjects and up to 5 HC subjects) may be asked to return for a second injection and scanning procedure to evaluate the reproducibility of the imaging measure using this procedure. Subjects may decline participation in the second scan. Subjects will be requested to return for this second scan until enough second scan data is collected to evaluate the imaging outcome measure for reproducibility.
Interventions
DRUG[18F] CFPyPB
Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
Sponsors
Institute for Neurodegenerative Disorders
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
PD subject inclusion criteria: * The participant is 30 years or older. * Written informed consent is obtained. * Participants have a diagnosis of PD (based on UK Brain Bank Criteria). * Modified Hoehn and Yahr stage of 1 - 4. * For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\] CFPyPB injection. PD subject
Exclusion criteria
* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. * The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion. * The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * The subject has any contraindication to MRI examination, e.g. metal implants or phobia as determined by the onsite radiologist performing the scan. * The subject is a pregnant or nursing mother AD subject inclusion criteria: * The participant is 50 years or older. * Written informed consent is obtained. * Participants have a clinical diagnosis of probable Alzheimer disease in accordance with the DSM-IV-TR and according to (NINCDS/ADRDA) criteria. * Participants do not fulfill the ICC criteria for probable DLB, the NINDS-AIREN for probable vascular dementia, or the Neary \[Neary, et al. 1998\] criteria for FTD. * Clinical Dementia Rating Scale score 0.5, 1 or 2. * Modified Hachinski Ischemia Scale score of ≤ 4. * Geriatric Depression Scale (GDS) ≤ 10. * For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\] CFPyPB injection. AD subject
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the dynamic uptake and washout of [18F] CFPyPB | Approximately 2 years | To assess the dynamic uptake and washout of \[18F\] CFPyPB, an imaging tracer targeting the glycine transporter-1 (GlyT1) receptor in brain, using positron emission tomography (PET) in subjects with Parkinson disease (PD) Alzheimer disease (AD) and healthy controls (HC). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perform blood metabolite characterization of [18F] CFPyPB | Approximately 2 years | To perform blood metabolite characterization of \[18F\] CFPyPB in subjects with PD, AD and HC to determine the nature of metabolites in assessment of \[18F\] CFPyPB as a single positron computed tomography (PET) brain imaging agent. |
| To obtain safety data | Approximately 2 years | To acquire safety data following injection of \[18F\] CFPyPB |
| Obtain test/retest reproductibility | Approximately 2 years | To obtain test/retest reproducibility of quantitative PET outcome measures with \[18F\] CFPyPB |
Countries
United States
Outcome results
None listed